Shortened Spadin Analogs Display Better TREK-1 Inhibition, In Vivo Stability and Antidepressant Activity.
Low Confidence Animal StudyPrimary source: [Open]
Linked compounds: pe-22-28
Outcomes summary
Preclinical study describing PE 22-28 as a shortened spadin-derived peptide that inhibits the TREK-1 channel in vitro and shows antidepressant-like effects across multiple rodent behavioral models, alongside reported effects on neurogenesis/synaptogenesis markers.
Limitations
Preclinical models; behavioral endpoints do not guarantee clinical antidepressant efficacy; results depend on peptide identity, formulation, and experimental conditions.
Notes
Primary source: PMID 28955242.